Hepatamin Injection (Military Supply Name: Amino Acid Injection 250 Milliliters, Aminoacids Injection 250 ml)

Adult administration

Administer 500 to 1000 mL as a slow intravenous infusion. The rate is based on 180 to 300 minutes per 500 mL (approximately 40 to 50 drops per minute). For central venous administration, 500 to 1000 mL should be mixed with dextrose solutions and continuously infused over 24 hours.

This medication must be used only under the direction of a physician. It should not be used in patients with severely impaired kidney function or elevated blood nitrogen levels. Patients with metabolic disorders of amino acids other than liver dysfunction should also not be administered this medication. Patients with metabolic disorders that interfere with nitrogen utilization, severe heart failure, or pulmonary edema should avoid this medication. Patients with very low or no urine output, those with acidosis, or patients with excessive body fluid should not receive this treatment as well. Caution is advised for patients experiencing edema due to heart failure or sodium retention, or in patients with impaired kidney function. This medication contains sodium bisulfite, which can cause allergic reactions or asthma attacks, so patients with asthma should exercise special caution. Rarely, skin rashes or gastrointestinal symptoms like nausea and vomiting, as well as heart-related symptoms like palpitations or elevated blood pressure, may occur, and use should be discontinued immediately if any abnormal symptoms arise. Rapid large doses can lead to metabolic acidosis, so it is safer to administer slowly. When using this medication, observe symptoms such as chills, fever, headache, and difficulty breathing closely. Patients with weak kidney function may have elevated blood urea nitrogen levels, so regular monitoring is necessary. When this drug is used in combination with other medications, interactions may occur, so consultation with a physician or pharmacist is essential. Safety has not been established for pregnant women, so it should only be administered if absolutely necessary. Children or newborns may have immature liver function, so they should receive lower doses, and blood ammonia levels should be monitored frequently. Elderly patients may have decreased physical function, so administration should be slower and doses adjusted. This medication contains electrolytes, so when administered in large amounts, attention should be paid to electrolyte balance, and it should be administered slowly intravenously. The injection solution must be prepared and stored in a sterile condition, and solutions that are discolored or cloudy should not be used. When storing, do not open the packaging, and it should be used within 24 hours if refrigerated.

Serious side effects

• Hypersensitivity reactions such as rash
• difficulty breathing
• respiratory arrest
• shock
• bronchospasm
• anaphylactic shock
• asthma attacks.

Mild side effects

• Rash
• nausea
• vomiting
• discomfort in the chest
• palpitations
• rapid heart rate (tachycardia)
• elevated blood pressure
• acidosis
• chills
• fever

This medication should be stored in a tightly sealed container to prevent air or moisture from entering and should be kept out of direct sunlight at room temperature. Storing at a general temperature that is neither too warm nor too cold will help maintain the efficacy of the drug.

Appearance

This medication contains a colorless to pale yellow transparent solution in a polypropylene aqueous injection container.

Package unit

250 milliliters/box, 500 milliliters/box